Initially, the addition of Bevacizumab, a monoclonal antibody for VEGF, to standard chemotherapy produced significant clinical benefit in patients with previously untreated and pretreated metastatic colorectal cancer, advanced non-small cell lung cancer, and metastatic breast cancer [51]. Here, VEGFA is linked to non-small cell lung carcinoma.